Last update 01 Nov 2024
Biomedica Management Corp.

Biomedica Management Corp.

Private Company|
1999|
Maryland, United States
|
< 10
|
www.biomedic.net

Overview

Related

4
Drugs associated with Biomedica Management Corp.
OC-229
Target
Selectins
Mechanism
Selectins inhibitors
Active Org.-
Originator Org.
Ontogen Corp.
Active Indication-
Inactive Indication
Reperfusion Injury
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
EC-234
Target
TNF
Mechanism
TNF inhibitors
Active Org.-
Originator Org.
Biomedica Management Corp.Biomedica Management Corp.
Active Indication-
Inactive Indication
Perioperative ischaemia [+1]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
Glyco-23
Target
Cell adhesion molecule
Mechanism
Cell adhesion molecule modulators
Active Org.-
Originator Org.
Biomedica Management Corp.Biomedica Management Corp.
Active Indication-
Inactive Indication
Sepsis
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Biomedica Management Corp.
NCT02264730 / Unknown statusPhase 1
Phase 1 Single-Arm Study Evaluating ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery in Which Liver Bleeding is Encountered
100 Clinical Results associated with Biomedica Management Corp.
Login to view more data
0 Patents (Medical) associated with Biomedica Management Corp.
Login to view more data
100 Deals associated with Biomedica Management Corp.
Login to view more data
100 Translational Medicine associated with Biomedica Management Corp.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
4
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
OC-229
 ( Selectins )		Reperfusion Injury
More
Discontinued
EC-234
 ( TNF )		Reperfusion Injury
More
Discontinued
Glyco-23
 ( Cell adhesion molecule )		Sepsis
More
Pending
EC-234/OC-229
 ( P-sel x TNF )		Reperfusion Injury
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free